My PhD is based on 2 main articles already published (attached). These 2 studies should be merged in one document for the thesis. The structure should be: introduction, methodology, results, discussion and conclusions.
The PhD should also mention the following articles:
Jae H. Park, Karthik Nath, Sean M. Devlin, Craig S. Sauter, M. Lia Palomba1, Gunjan Shah1, Parastoo Dahi, Richard J. Lin, Michael 30 Scordo, Miguel-Angel Perales, Roni Shouval, Ana Alarcon Tomas, Elizabeth Cathcart, Elena Mead, Bianca Santomasso, Andrei Holodny, Renier, J. Brentjens, Isabelle Riviere, Michel Sadelai. Anti-CD19 CAR T cell therapy and prophylactic anakinra in relapsed 26 or refractory lymphoma: phase 2 trial interim results. Accepted Nature Medicine. NMED-A124893C
Roni Shouval, Adam Goldman, Jessica Flynn, Ahmed El-Moghraby, Mahin Rehman, Sean Devlin, Ana Alarcon Tomas, Magdalena Corona, John Slingerland, Allison Parascondola, Amethyst Saldia, Ivan Landego, Richard J. Lin, Michael Scordo, Sandeep Raj, Sergio A. Giralt, M. Lia Palomba, Parastoo B. Dahi, Moneeza Walji, Gilles Salles, Karthik Nath, Mark B. Geyer, Jae H. Park, Joshua A. Fein, Ioanna Kosmidou, Marcel R.M. van den Brink, Gunjan L. Shah, Jennifer Liu, Miguel-Angel Perales, and Syed S. Mahmoo. Atrial Arrhythmias Following CAR-Chimeric Antigen Receptor T-cell Therapy: Incidence, Risk Factors, and Inflammatory Profile. Accepted European heart journal EURHEARTJ-D-23-01711.
Wudhikarn K, Alarcon Tomas A, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2022 Nov
Nath K, Wudhikarn K, Alarcon Tomas A, Perales MA. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert Opin Drug Saf. 2023 Jan;22(1):5-15. doi: 10.1080/14740338.2023.2177268. Epub 2023 Feb 17. PMID: 36737060; PMCID: PMC9975047.
Miriam Sanchez-Escamilla, Jessica Flynn, Sean 3 Devlin, Molly Maloy, Samira A Fatmi, Ana Alarcon Tomas, Silvia Escribano-Serrat, Doris Ponce, Craig S Sauter, Sergio A. Giralt, Scordo, Miguel-Angel Perales. EASIX Score Predicts Inferior Survival After Allogeneic Hematopoietic Cell Transplantation. Accepted for publication BMT journal BMT-2022-446RR.
Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, Harchandani B, Perales MA, Geyer MB, Park JH, Palomba ML, Shouval R, Tomas AA, Shah GL, Yang EH, Gaut DL, Rothberg MV, Horn EM, Leonard JP, Van Besien K, Frigault MJ, Chen Z, Mehrotra B, Neilan TG, Steingart RM. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023 Mar 20:ehad117. doi: 10.1093/eurheartj/ehad117. Epub ahead of print. PMID: 36939851.
Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, Devlin S, Wijetunga NA, Tringale KR, Batlevi C, Dahi P, Giralt S, Lin R, Park J, Scordo M, Sauter C, Shah G, Hajj C, Salles G, Schoder H, Palomba ML, Perales MA, Yahalom J, Imber BS. Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2022 Dec
Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Alarcon Tomas A, Bishop MR, McGuirk JP, Maziarz RT, Chen A, Bachanova V, Maakaron J, Riedell PA, Oluwole OO. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2022 Dec
Fried S, Shouval R, Walji M, Flynn JR, Yerushalmi R, Shem-Tov N, Danylesko I, Tomas AA, Fein JA, Devlin SM, Sauter CS, Shah GL, Kedmi M, Jacoby E, Shargian L, Raanani P, Yeshurun M, Perales MA, Nagler A, Avigdor A, Shimoni A. Allogeneic Hematopoietic Cell Transplantation After CAR T-cell Therapy in Large B-cell Lymphoma: Allogeneic-HCT after CAR T-cell therapy. Transplant Cell Ther. 2022
Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO,
Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2022 Jul 14.
Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2022 Jul 14.
Nath K, Tomas AA, Flynn J, Fein JA, Alperovich A, Anagnostou T, Batlevi CL, Dahi PB, Fingrut WB, Giralt SA, Lin RJ, Palomba ML, Peled JU, Salles G, Sauter CS, Scordo M, Fraint E, Feuer E, Shah N, Slingerland JB, Devlin S, Shah GL, Gupta G, Perales MA, Shouval R. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. Transplant Cell Ther. 2022
Roni Shouval, Joshua Alexander Fein, Christina Cho, Scott Avecilla, Josel D Ruiz, Ana Alarcon Tomas, Miriam Sanchez-Escamilla, Nerea Castillo Flores, Lucrecia Yanez San Segundo, Juliet N. Barker, Parstoo B. Dahi, Sergio Giralt, Alexander Geyer, Boglarka Gyurkocza, Ann A Jakubowski, Richard J Lin, Richard J O’Reilly, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M Ponce, Craig S. Sauter, Michael Scordo, Brian Shaffer, Gunjan Shah, James P Sullivan, Roni Tamari, Marcel R. M. RM van den Brink, James W Young, Arnon Nagler, Sean M. Devlin, Avichai Shimoni, Miguel-Angel Perales; The Simplified Comorbidity Index (SCI) – a new tool for prediction of non-relapse mortality in allogeneic HCT. Blood Adv 2021.
Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, Batlevi C, Brentjens RJ, Dahi PB, Devlin SM, Diamonte C, Giralt S, Halton EF, Jain T, Maloy M, Mead E, Palomba ML, Ruiz J, Santomasso B, Sauter CS, Scordo M, Shah GL, Park JH, Yanez San Segundo L, Perales MA. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021
Lin RJ, Baser RE, Elko TA, Korc-Grodzicki B, Shahrokni A, Maloy MA, Young JW, Tamari R, Shah GL, Shaffer BC, Scordo M, Sauter CS, Ponce DM, Politikos I, Perales MA, Papadopoulos EB, Gyurkocza B, Dahi PB, Cho C, Barker JN, Tomas AA, Flores NC, Sanchez-Escamilla M, Segundo LYS, Jakubowski AA, Giralt SA. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021.
Corona M, Shouval R, Alarcón A, Flynn J, Devlin S, Batlevi C, Mantha S, Palomba ML, Scordo M, Shah G, Sauter C, Perales MÁ, Dahi PB. Management of prolonged cytopenia following CAR T-cell therapy. Bone Marrow Transplant. 2022 Sep 21.
Kitsada Wudhikarn, Ana Alarcón Tomás, Kazunori Murata, Miguel-Angel Perales, Chapter 8 – Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers, Editor(s): Lakshmi V. Ramanathan, Martin Fleisher, Michael J. Duffy, In Clinical Aspects and Laboratory Determination, Cancer Biomarkers, Elsevier, 2022, Pages 245-281, ISBN 9780128243022